Persistent humoral, cellular, and transcriptional signatures associated with protective immunity against SARS-CoV-2 observed 18-months after COVID-19 vaccinations during the Omicron wave in Pakistan
This study demonstrates that 18 months after vaccination in Pakistan, a population with limited booster access maintained robust humoral, cellular, and transcriptional immune signatures against SARS-CoV-2, suggesting that hybrid immunity from vaccination and natural infection provided durable protection with low morbidity and mortality.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Imagine your body as a bustling, high-tech city. When a dangerous invader like a virus tries to break in, the city doesn't just rely on one type of guard. It has a "Humoral" force, which is like a fleet of specialized drones (antibodies) that patrol the skies and neutralize threats from a distance. It also has a "Cellular" army (T-cells), which are the ground troops ready to hunt down and destroy infected buildings. Finally, there's the "Transcriptional" blueprint—the city's central computer code that tells the guards when to wake up, how to build new weapons, and how to remember past battles. Scientists have been trying to figure out how long these defenses stay active after a vaccination, especially in places where the virus keeps showing up. The big question is: Does the protection fade away like a forgotten password, or does it evolve into a permanent, upgraded security system? This is particularly important for countries that didn't have access to the latest "booster" updates, to see if their natural defenses and earlier vaccines were enough to keep the city safe.
This study, conducted in Pakistan, decided to check the city's security status 18 months after people received their first round of COVID-19 vaccines. The researchers looked at a group of healthy adults who had received different types of vaccines—some got "inactivated" virus shots (like a training dummy), some got "mRNA" shots (like a detailed blueprint), and others got "vector" shots (like a delivery truck carrying instructions). They wanted to see if the immune system was still on high alert against the virus, even as new variants like Omicron were circulating.
The results were surprisingly robust. When the team checked the "drones" (antibodies), they found that the levels hadn't just stayed steady; they had actually gone up over time. By the 18-month mark, nearly everyone (99%) still had high levels of antibodies against the virus's "spike" protein, and about 97% had them against the "RBD" part of the spike. Interestingly, the people who received the mRNA vaccines had the highest antibody levels, followed by those with vector vaccines, and then the inactivated ones. But here's the kicker: even the group with the lowest levels still had strong protection.
The "ground troops" (T-cells) were also still very much on the job. About 69% of the participants showed a strong T-cell reaction to the virus 18 months later. The study noted that men seemed to have a slightly more active cellular response than women, and younger people (ages 18–30) had stronger responses than those over 50. While the mRNA group still showed the strongest cellular response, the fact that anyone in the inactivated or vector groups still had such a strong memory of the virus after a year and a half without extra boosters was a major finding.
To understand why this protection was lasting, the scientists looked at the "city's computer code" (transcriptional profiles). They compared the blood samples of these vaccinated people to samples from healthy people taken before the pandemic existed. They found that the vaccinated group had a distinct "signature" of activity. Their cells were buzzing with activity related to inflammation, stress responses, and protein synthesis. It was as if the city's computer had rewritten its operating system to stay in a state of "trained readiness." The study found that pathways associated with fighting infections (like Toll-like receptors) and even some stress pathways (like cellular senescence) were turned on. This suggests that the combination of the vaccines and the natural, low-level exposure to the virus in the community created a "hybrid immunity." This hybrid state seems to have trained the immune system to stay alert and effective for a long time, even without the extra "booster" shots that were common in wealthier countries.
The researchers also compared their data with a similar study from Japan that looked at people 180 days (6 months) after vaccination. While the Japanese study saw signs of immunity starting to fade, the Pakistani study, looking at 18 months, saw sustained activation. This suggests that in places where the virus is constantly circulating, the immune system gets frequent "refresher courses" from natural exposure, keeping the defenses sharp. The study concludes that this "hybrid immunity"—a mix of vaccination and natural infection—likely provided long-term protection in Pakistan, resulting in lower sickness and death rates compared to countries that relied solely on vaccines and boosters. The authors note that while participants self-reported no history of COVID-19, the study did not have the capacity to test for active or chronic infections at the time of participation, meaning the exact contribution of recent infections versus the vaccine remains a mix. Ultimately, the paper paints a picture of an immune system that, when given a head start by vaccines and then kept active by the environment, can build a surprisingly durable shield.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.